You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Janus kinase 1 (JAK1) inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Sarcoidosis
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Jan 24, 2023

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Granuloma Annulare
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Dec 19, 2022

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Chronic Kidney Diseases Trial in Durham (Baricitinib, Placebo)

Recruiting
  • Chronic Kidney Diseases
  • Durham, North Carolina
    Duke Research at Pickett Road
Dec 15, 2022

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Itacitinib (INCB039110)
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jul 14, 2022

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

Active, not recruiting
  • Chronic Graft vs Host Disease
  • Chronic Graft-Versus-Host Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 29, 2022

COVID-19 Trial in Halifax (Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor),

Recruiting
  • COVID-19
  • Baricitinib (janus kinase inhibitor)
  • +3 more
  • Halifax, Nova Scotia, Canada
    Nova Scotia Health Authority
Mar 9, 2022

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

Recruiting
  • Rheumatoid Arthritis
  • +4 more
  • filgotinib 200mg/day
  • subcutaneous tocilizumab 162mg/biweekly
  • Nagasaki, Japan
    Nagasaki University Hospital
Oct 23, 2021

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Non-sclerotic Cutaneous Chronic Graft-versus-host Disease Trial in New York (topical ruxolitinib 1.5% cream, Topical

Recruiting
  • Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
  • topical ruxolitinib 1.5% cream
  • Topical vehicle/moisturizer cream
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 20, 2022

Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)

Recruiting
  • Lupus or SLE
  • Nephritis
  • Baricitinib 4 MG
  • +2 more
  • Assiut, Yes, Egypt
    Manal Hassanien
Jan 13, 2023

Myelofibrosis Trial in Worldwide (Imetelstat, Best Available Therapy (BAT))

Recruiting
  • Myelofibrosis
  • La Jolla, California
  • +165 more
Aug 19, 2022

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
Has Results
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
May 19, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

GastroEsophageal Cancer, Gastric Cancer Trial in New York (Lenvatinib, Pembrolizumab)

Recruiting
  • GastroEsophageal Cancer
  • Gastric Cancer
  • New York, New York
  • +1 more
Aug 12, 2022

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022